Circulating exosomal lncRNAs in patients with chronic coronary syndromes

Meili Zheng; Ruijuan Han; Wen Yuan; Hongjie Chi; Yeping Zhang; Kai Sun; Jiuchang Zhong; Xiaoyan Liu; Xinchun Yang

doi:10.5114/aoms/128014

Circulating exosomal lncRNAs in patients with chronic coronary syndromes

Arch Med Sci. 2021 Jan 8;19(1):46-56. doi: 10.5114/aoms/128014. eCollection 2023.

Authors

Meili Zheng^{1

2}, Ruijuan Han³, Wen Yuan⁴, Hongjie Chi^{1

2}, Yeping Zhang^{1

2}, Kai Sun⁵, Jiuchang Zhong^{1

2

4}, Xiaoyan Liu^{1

2

4}, Xinchun Yang^{1

2}

Affiliations

¹ Heart Center, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
² Beijing Key Laboratory of Hypertension Research, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
³ Department of Radiology, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
⁴ Medical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
⁵ Department of Radiology, Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen, China.

Abstract

Introduction: The concept of chronic coronary syndrome (CCS) was first presented at the European Society of Cardiology Meeting in 2019. However, the roles of exosomal lncRNAs in CCS remain largely unclear.

Material and methods: A case-control study was performed with a total of 218 participants (137 males and 81 females), including 15 CCS patients and 15 controls for sequencing profiles, 20 CCS patients and 20 controls for the first validation, and 100 CCS patients and 48 controls for the second validation. Exosomes were isolated from the plasma of CCS patients and controls, and exosomal lncRNAs were identified by sequencing profiles and verified twice by qRT-PCR analysis. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic value of exosomal lncRNAs for CCS patients.

Results: A total of 152 significantly differentially expressed lncRNAs with over two-fold changes were detected in plasma exosomes of CCS patients, including 90 upregulated and 62 downregulated lncRNAs. Importantly, 6 upregulated lncRNAs with the top fold changes were selected for validations. Exosomal lncRNAs ENST00000424615.2 and ENST00000560769.1 were significantly elevated in CCS patients in both validations compared with controls. The areas under the ROC of lncRNAs ENST00000424615.2 and ENST00000560769.1 were 0.654 and 0.722, respectively. Additionally, exosomal lncRNA ENST00000560769.1 was significantly higher in the CCS patients with more diseased vessels (p = 0.028).

Conclusions: Exosomal lncRNA ENST00000424615.2 and ENST00000560769.1 were identified as novel diagnosis biomarkers for patients with CCS. Moreover, exosomal lncRNA ENST00000560769.1 was significantly higher in the CCS patients with more diseased vessels, and might be associated with a poor prognosis.

Keywords: biomarkers; chronic coronary syndrome; coronary artery disease; exosomal lncRNAs.